SURTAVI
No differences in death ,stroke, MI, or HF between TAVR and Surgery during longer follow-up
#TCT2021
Hemodynamics
Total AR and PVL
KCCQ no difference after 1 year
NYHA class at one year 1
Summary for SURTAVI
Self expanding valve
#TCT2021
Excellent!
5 year data for 4,000 patients is now out (intermediate risk).
@djc795
Economic outcomes of PARTNER #3
@djc795
Cost effectiveness study along side of PARTNER 3 trial
funded by Edwards
Costing: definitions
US population only
Medicare data link
Results Baseline
TAVR vs SAVR PARTNER 3 Economic Study
Index Hospital Costs
Follow-up Cost
Overall no cost difference
QALY difference (borderline?!)
#TCT2021
All costs and effects discounting
TAVR is cost effective
Subgroups (pre-specified)
Sensitivity analyses
#TCT2021
Sensitivity Analyses
Summary!
84% CI that we will improve outcomes and at the same time achieve cost effectiveness.
10 year outcomes will affect cost effectiveness - to come...
Outstanding presentation @djc795 @DrMauricioCohen
#TCT2021
"When mortality rate is the same between SAVR and TAVR: patient preference is what matter next."
"No one wants a sternotomy."
@djc795
#TCT2021
CHOICE CLOSURE
Vascular Closure for TAVR but this also applies to shock space also (Safety Bundle)
#TCT2021
@Radial_ICG @behnam_tehrani @agtruesdell @ShashankSinhaMD @JACCJournals
Available Evidence
Aim Choice Closure
Randomization: pure plug based vs primary suture based
#TCT2021
Inclusion and Exclusion
Primary Endpoint
Secondary Endpoints
Study Methods
Angioseal was used...
3 Locations in Germany
#TCT2021
Study Flow
258 MANTA vs 258 ProGlide
#TCT2021
Baseline Results
Vessel Characteristics
Procedural Details
Low ultrasound use?! @Radial_ICG
#TCT2021
Manta had higher complications!!
Important data!
#TCT2021
Subgroup analysis
Hospital Outcomes
30-Day Outcomes
#TCT2021
Limitation
Conclusion
Excellent trial @Mo_A_W
Applies to shock too
***Editorializing: Losing the wire access with MANTA is a big problem.
#SafetyBundle
#TCT2021
Comparison of a Pure Plug-Based versus a Primary Suture-Based Vascular Closure Device Strategy for Transfemoral Transcatheter Aortic Valve Replacement: The CHOICE-CLOSURE Randomized Clinical Trial
@CircAHA
ahajournals.org/doi/abs/10.116…
Share this Scrolly Tale with your friends.
A Scrolly Tale is a new way to read Twitter threads with a more visually immersive experience.
Discover more beautiful Scrolly Tales like this.